Seamless Therapeutics Secures $25M Seed Round to Propel the Next Generation of CRISPR Gene Therapies

We are thrilled to announce that Seamless Therapeutics has successfully raised $25 million in new funding—a milestone that highlights not only the strong faith of our investors but also our unwavering commitment to revolutionizing precision medicine. Founded on the pioneering legacy of CRISPR Therapeutics, our company has grown over the past decade from a research-stage innovator into a recognized leader in gene editing technologies. This significant funding will enable us to expand our development of next-generation therapies that build upon the Nobel Prize-winning CRISPR technology, which has already redefined biomedical research with transformative clinical outcomes. Seamless Therapeutics is dedicated to advancing a robust pipeline of product candidates targeting a diverse range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. The capital infusion will support key research and development initiatives aimed at accelerating clinical trials, optimizing manufacturing processes, and forging strategic partnerships with other leading entities in the biotech industry. By enhancing our ability to navigate the complexities of gene editing and its applications, this funding round will empower us to deliver innovative, life-changing treatments to patients worldwide. Operating with a multidisciplinary team and state-of-the-art R&D facilities both in the United States and Europe, Seamless Therapeutics remains fully committed to pushing the boundaries of what's possible in medicine. As we embark on this exciting new chapter, we look forward to driving forward our vision of transforming patient care with breakthrough therapies that exemplify the true potential of modern biotechnology.